A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

NCT05059223 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Narcolepsy
Cataplexy
Excessive Daytime Sleepiness

Interventions

DRUG: AXS-12 (reboxetine)
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.